| July 2014 |
- CureApp, Inc was established.
|
| December 2014 |
- Selected for "I-Challenge! (the ICT Innovation Creation Challenge Program)" sponsored by the Ministry of Internal Affairs and Communications.
|
| February 2015 |
- Procured approximately 30 million yen by raising capital through third-party allocation.
- Started clinical research on Prescription Digital Therapeutic App for Nicotine Addiction at Keio University Hospital.
|
| October 2015 |
- Procured approximately 70 million yen by raising capital through third-party allocation.
- Granted the The Ministry of Economy, Trade and Industry "Monodzukuri Grant".
|
| November 2015 |
- Made the decision to adopt NEDO "research and development type venture support".
|
| February 2016 |
- Achieved second-class medical device manufacturing and sales business status.
|
| October 2016 |
- Started NASH (Non-Alcoholic Steatohepatitis) clinical research of therapeutic applications with The Department of Gastroenterology of The University of Tokyo Medical School Hospital.
- Obtained an Information Security Management System (ISMS).
|
| January 2017 |
- Selected for the "HIYAKU Next Enterprise" Program sponsored by the Ministry of Economy, Trade and Industry (dispatched to Silicon Valley).
|
| February 2017 |
- Procured approximately 380 million yen by raising capital through third-party allocation.
|
| April 2017 |
- Launched the "ascure program for Smoking Cessation" as the first series of our EHB (Employee Health Benefit) Platform.
|
| October 2017 |
- Started clinical trail on Prescription Digital Therapeutic App for Nicotine Addiction.
|
| February 2018 |
- Procured approximately 1.5 billion yen by raising capital through third-party allocation.
|
| March 2018 |
- Acquired the "Privacymark (P mark)," provided by JIPDEC.
|
| June 2018 |
- Started clinical research on Prescription Digital Therapeutic App for Hypertension at multiple institutions, including Jichi Medical University Hospital.
- Selected for the "J-Startup" Program sponsored by the Ministry of Economy, Trade and Industry.
|
| March 2019 |
- Established CureApp North America, Inc.
|
| May 2019 |
- Announced the results of Japan's first "clinical test of an app" at the American Thoracic Society 2019 International Conference.
- Announced the effectiveness of Prescription Digital Therapeutic App for Nicotine Addiction in smoking cessation outpatient clinics via Phase III clinical trials in Japan.
|
| August 2019 |
- Procured approximately 2.3 billion yen by raising capital through third-party allocation.
|
| May 2020 |
- The First Phase 3 Clinical Trials of Prescription Digital Therapeutic App for Hypertension begin in Japan.
|
| June 2020 |
- CureApp Awarded as Technology Pioneer by World Economic Forum.
|
| August 2020 |
- CureApp Named to the 2020 CB Insights Digital Health 150 -- List of Most Innovative Digital Health Startups.
- Asia’s First Prescription “Prescription Digital Therapeutics” Approved in Japan ; Prescription Digital Therapeutic App for Nicotine Addiction with CO Checker Receives Regulatory Approval.
|
| Nobember 2020 |
- Partnered with Daiichi Sankyo INC. to develop a Prescription Digital Therapeutic App for Breast Cancer.
|
| December 2020 |
- CureApp SC, Prescription Digital Therapeutic App for Nicotine Addiction: Introducing a New Form of App-based Prescription Treatment Reimbursed in Japan’s Public Healthcare Insurance System.
|
| March 2021 |
- Raised over 2.1 billion yen by through an allocation of newly issued common stock, reaching a cumulative of over 6.4 billion yen to date.
- Prescription Digital Therapeutic App for Hypertension, has completed a Japanese Phase III multi-center randomized controlled trial. The research for the app was carried out in collaboration with a team led by Professor Kazuomi Kario at Jichi Medical University.
|
| May 2021 |
- Started clinical trial for Prescription Digital Therapeutic App for Alcoholism at Okayama City Hospital in Japan.
|
| July 2021 |
- CureApp launches the ascureDr. program for Smoking Cessation treatment as part of our EHB platform.
|
| August 2021 |
- Selected for the Tokyo Metropolitan Government Project to Build Next-Generation Wellness Solutions. (Content related to the development of a program to prevent serious diseases, specializing in hypertension prevention)
- Presented the clinical trial results of Prescription Digital Therapeutic App for Hypertension at ESC Congress 2021, and published the results in the European Heart Journal.
|
| September 2021 |
- CureApp was selected for the Tokyo Metropolitan Government’s Startup Promotion Project, PoC Ground Tokyo.
|
| October 2021 |
- Project for the development of Prescription Digital Therapeutic App for Alcoholism has been chosen for AMED's Medical-Industrial Collaboration Innovation Promotion Project.
|
| November 2021 |
- Added a page about sustainability efforts.
- Listed on Nikkei Trendy (a Japanese business newspaper) "2022 Hit Prediction Ranking".
- ascure program for Smoking Cessation was offered In "POC GROUND TOKYO" in the Tokyo Metropolitan Startup Supplementary Experiment Promotion Project.
|
| December 2021 |
- Partnered with a medical corporation Yumino to develop a Prescription Digital Therapeutic App for Chronic Heart Failure.
- Won the Minister of Economy, Trade and Industry in the 21st JAPAN Venture Awards.
- "2021 Japan Excellent Products and Service Award" Winner award.
|
| April 2022 |
- Received the Marketing authorization (Regulatory Approval) for the “Prescription Digital Therapeutic App for Hypertension”.
|
| June 2022 |
- Paper about cost-effectiveness of Prescription Digital Therapeutic App for Hypertension is published in Hypertension Research Journal.
|
| August 2022 |
- A license agreement with Sawai Group Holdings for the development and marketing of Prescription Digital Therapeutic App for NASH.
|
| September 2022 |
- Prescription Digital Therapeutic App for Hypertension: Introducing a New Form of App-based Prescription Treatment Reimbursed in Japan’s Public Healthcare Insurance System.
|
| Norbember 2022 |
- Partnered with Fukusima Medical University to develop a Prescription Digital Therapeutic App for Chronic Low Back Pain.
|
| December 2022 |
- Started clinical trial for Prescription Digital Therapeutic App for Alcoholism.
|
| January 2023 |
- "ascure program for Smoking Cessation," a fully online smoking cessation program, adopted by over 300 employers and health insurance associations as EHB.
|
| June 2023 |
- Received Judging Committee's Special Award of Startup Award 2023 (NIPPON STARTUP AWARD)
|
| September 2023 |
- Selected for the GSAP (Global Startup Acceleration Program) hosted by Alchemist and JETRO
|
| October 2023 |
- Selected for the “J-Startup Impact” （startup development support program）sponsored by the Ministry of Internal Affairs and Communications.
- ascure program for Smoking Cessation” was adopted as Osaka City’s smoking cessation support program and introduced to 350 health insurance associations, employers and other municipalities.
|
| December 2023 |
- "2023 Japan Excellent Products and Service Award" Nikkei Industry Newspaper Award.
|
| February 2024 |
- "The 5th IP BASE AWARD Startup Division” Encouragement Prize Winner.
- Started clinical trial for Prescription digital Therapeutic App for NASH (Non-Alcoholic Steatohepatitis).
|
| May 2024 |
- Ranked in the” World's Best Digital Health Companies 2024” list
|
| February 2025 |
- Received the Marketing authorization (Regulatory Approval) for the “Prescription Digital Therapeutic App for Alcoholism”.
|
| September 2025 |
- Prescription Digital Therapeutic App for Alcoholism: Introducing a New Form of App-based Prescription Treatment Reimbursed in Japan’s Public Healthcare Insurance System.
|
